Context Treatment of metastatic urothelial carcinoma is currently undergoing a rapid
evolution. Objective This overview presents the updated European Association of Urology …

Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

PURPOSE Cisplatin-based combination chemotherapy remains the standard of care for
locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial …

Background Survival outcomes are poor for patients with metastatic urothelial carcinoma
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …

Background The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma
after radical surgery is not clear. Methods In a phase 3, multicenter, double-blind …

Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with
localized urothelial carcinoma,, with one study reporting data in cisplatin-ineligible patients …

Purpose To determine the activity of pembrolizumab as neoadjuvant immunotherapy before
radical cystectomy (RC) for muscle-invasive bladder carcinoma (MIBC) for which standard …

Background Locally advanced or metastatic urothelial carcinoma is generally incurable and
has scarce treatment options, especially for cisplatin-ineligible patients previously treated …